- Home
- MNRO vs ABVX Comparison
MNRO vs ABVX Comparison
Compare MNRO & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNRO
- ABVX
- Stock Information
- Founded
- MNRO 1957
- ABVX 2013
- Country
- MNRO United States
- ABVX France
- Employees
- MNRO N/A
- ABVX N/A
- Industry
- MNRO Automotive Aftermarket
- ABVX
- Sector
- MNRO Consumer Discretionary
- ABVX
- Exchange
- MNRO Nasdaq
- ABVX Nasdaq
- Market Cap
- MNRO 658.9M
- ABVX 722.3M
- IPO Year
- MNRO 1991
- ABVX N/A
- Fundamental
- Price
- MNRO $18.71
- ABVX $8.08
- Analyst Decision
- MNRO Hold
- ABVX Strong Buy
- Analyst Count
- MNRO 2
- ABVX 7
- Target Price
- MNRO $25.50
- ABVX $37.86
- AVG Volume (30 Days)
- MNRO 956.1K
- ABVX 162.8K
- Earning Date
- MNRO 01-29-2025
- ABVX 03-24-2025
- Dividend Yield
- MNRO 5.99%
- ABVX N/A
- EPS Growth
- MNRO N/A
- ABVX N/A
- EPS
- MNRO 0.62
- ABVX N/A
- Revenue
- MNRO $1,210,419,000.00
- ABVX $9,676,417.00
- Revenue This Year
- MNRO N/A
- ABVX $31.67
- Revenue Next Year
- MNRO $2.64
- ABVX $759.77
- P/E Ratio
- MNRO $30.34
- ABVX N/A
- Revenue Growth
- MNRO N/A
- ABVX 100.87
- 52 Week Low
- MNRO $18.29
- ABVX $5.50
- 52 Week High
- MNRO $33.98
- ABVX $17.02
- Technical
- Relative Strength Index (RSI)
- MNRO 33.04
- ABVX 75.42
- Support Level
- MNRO $18.74
- ABVX $5.88
- Resistance Level
- MNRO $19.92
- ABVX $7.57
- Average True Range (ATR)
- MNRO 0.70
- ABVX 0.46
- MACD
- MNRO 0.14
- ABVX 0.24
- Stochastic Oscillator
- MNRO 22.70
- ABVX 97.68
About MNRO Monro Inc.
Monro Inc is a provider automobile service stations in the United States. Through its network of company-owned service stations, Monro Muffler Brake offers maintenance, repair, tire, and fleet management services for automobiles focused largely on undercar services such as brake, steering, exhaust, drivetrain, and suspension systems. Next to service stores, the company also offers tire stores specialised in tire replacement and service.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.